ARCHIVES

Drug Cleared For GIST And Kidney Cancer, FDA’s First Two-Indication Cancer Approval

This article is from The Cancer Letter archive.

Vol. 29 No. 1 | January 27, 2006

Download PDF Visit The Full Archive

Related Articles

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

November 16, 2012

NCI Plans Research To Reduce Cancer Disparities.

June 16, 2000

Working Group To Review NCI Clinical Trials Programs

April 12, 1996

Endostatin Enters Phase II Trial For Neuroendocrine Tumors.

December 14, 2001

Scientific, Funding Challenges Test NCI Prevention Effort, Broder Says In First Speech to DCPC Board

February 3, 1989

Protocols Approved During The Month of September 2001

October 26, 2001